Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Atrys Health's share price for the quarter that ended in Dec. 2025 was €2.93. Atrys Health's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 75.9 Mil. Therefore, Atrys Health's market cap for the quarter that ended in Dec. 2025 was €222.4 Mil.
Atrys Health's quarterly market cap
declined
from Dec. 2024 (€255.8 Mil) to Jun. 2025 (€194.2 Mil) but then
increased
from Jun. 2025 (€194.2 Mil) to Dec. 2025 (€222.4 Mil).
Atrys Health's annual market cap
declined
from Dec. 2023 (€278.7 Mil) to Dec. 2024 (€255.8 Mil) and
declined
from Dec. 2024 (€255.8 Mil) to Dec. 2025 (€222.4 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Atrys Health's Enterprise Value for Today is €439.5 Mil.
Atrys Health (XMAD:ATRY) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Atrys Health Market Cap Related Terms
Atrys Health Market Cap Historical Data
* Premium members only.
The historical data trend for Atrys Health's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:ATRY vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Atrys Health's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Atrys Health Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Atrys Health's Market Cap distribution charts can be found below:
* The bar in red indicates where Atrys Health's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Atrys Health's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Atrys Health (XMAD:ATRY) has a Market Cap of €194.7 Mil as of Jun. 25, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Atrys Health and its competitors. According to the industry distribution chart, Atrys Health ranks #575 out of 1431 companies in the Biotechnology industry, placing it in the top 40.2%.
Is Atrys Health's Market Cap too high?
Atrys Health's current Market Cap is €194.7 Mil. Based on the distribution chart, Atrys Health ranks #575 out of 1431 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Atrys Health has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Atrys Health's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Atrys Health ranks #575 out of 1431 companies for Market Cap. This puts Atrys Health in the upper half of its industry. The industry median Market Cap is 117.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 117.63, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Atrys Health and its competitors. For the Biotechnology industry, the median Market Cap is 117.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Atrys Health's current Market Cap is €194.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrys Health stock overvalued right now?
Based on GuruFocus' analysis, Atrys Health (XMAD:ATRY) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.11, compared to a current price of €2.57 — trading 17.5% below its estimated fair value. The current Market Cap is €194.7 Mil. Atrys Health's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Atrys Health (XMAD:ATRY), the current Market Cap is €194.7 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Atrys Health (XMAD:ATRY) Overvalued in 2026?
Based on GuruFocus' analysis, Atrys Health stock appears to be undervalued.
The current stock price of €2.57 is trading 17.5% below its estimated GF Value™ of €3.11.
GuruFocus considers Atrys Health to be Modestly Undervalued.
Key valuation signals for XMAD:ATRY:
Market Cap: €194.7 Mil
GF Value™: €3.11 vs. price of €2.57 (17.5% below fair value)
No single metric tells the full story. See the XMAD:ATRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Atrys Health SA is a Spain based biomedical company which focuses on developing tools for the diagnosis and treatment of cancer and precancerous conditions. It offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics. The company uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology.
68GF Score
Get the complete analysis for XMAD:ATRY
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:ATRY has been successfully added to your 
